Logo image
Back
A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis
Journal article   Open access   Peer reviewed

A randomized trial of vonapanitase (PATENCY-1) to promote radiocephalic fistula patency and use for hemodialysis

Anthony J. Bleyer, Vincent A. Scavo, Samuel E. Wilson, Barry J. Browne, Brian L. Ferris, C. Keith Ozaki, Timmy Lee, Eric K. Peden, Bradley S. Dixon, Rick Mishler, …
Journal of vascular surgery, Vol.69(2), pp.507-515
02/2019
DOI: 10.1016/j.jvs.2018.04.068
PMID: 30683197
url
https://doi.org/10.1016/j.jvs.2018.04.068View
Published (Version of record) Open Access

Abstract

Arteriovenous fistulas created in patients with chronic kidney disease often lose patency and fail to become usable. This prospective trial evaluated the efficacy of vonapanitase, a recombinant human elastase, in promoting radiocephalic fistula patency and use for hemodialysis. PATENCY-1 was a double-blind, placebo-controlled trial that enrolled 349 patients on or approaching hemodialysis and being evaluated for radiocephalic arteriovenous fistula creation. Of these, 313 were randomized and 311 treated. Patients were assigned to vonapanitase (n = 210) or placebo (n = 103). The study drug solution was applied topically to the artery and vein for 10 minutes immediately after fistula creation. The primary and secondary end points were primary patency (time to first thrombosis or corrective procedure) and secondary patency (time to abandonment). Tertiary end points included use of the fistula for hemodialysis, fistula maturation by ultrasound, and procedure rates. The Kaplan-Meier estimates of 12-month primary patency were 42% (95% confidence interval [CI], 35-49) and 31% (95% CI, 21-42) for vonapanitase and placebo (P = .25). The Kaplan-Meier estimates of 12-month secondary patency were 74% (95% CI, 68-80) and 61% (95% CI, 51-71) for vonapanitase and placebo (P = .048). The proportions of vonapanitase and placebo patients were 39% and 25% (P = .035) with unassisted use for hemodialysis and 64% and 44% (P = .006) with unassisted plus assisted use. Vonapanitase treatment did not significantly improve primary patency but was associated with increased secondary patency and use for hemodialysis. Further research is needed to evaluate these end points. [Display omitted]
 Fistula Hemodialysis access Radiocephalic Randomized, clinical trial Vonapanitase

Details

Metrics

24 Record Views
40 Times Cited - Web of Science
Logo image